Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 27, 2018
Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections
BOSTON, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today ...
November 27, 2018
Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
WATERTOWN, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (ALRN), the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and ...
November 27, 2018
BrainsWay: TMS Associates of Pennsylvania First Facility in the State to Treat Obsessive-Compulsive Disorder (OCD) with Deep Transcranial Magnetic Stimulation (Deep TMS)
HAVERFORD, Pa., Nov. 27, 2018 (GLOBE NEWSWIRE) -- TMS Associates of Pennsylvania LLC, Haverford’s leading mental health provider specializing in mood disorders, announced today that ...
November 27, 2018
Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and ...
November 27, 2018
Publication of manuscript on preclinical Proof-of-Concept of arimoclomol in Gaucher disease
Copenhagen, November 27, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with rare diseases, today announced that a manuscript ...
November 27, 2018
MannKind Appoints Christine Mundkur to its Board of Directors
WESTLAKE VILLAGE, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) today announced that Christine Mundkur has joined its Board of Directors, effective November ...
November 27, 2018
Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
GAITHERSBURG, Md., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company, today announced the appointment of Vipin K. Garg, Ph.D. as ...
November 19, 2018
Foamix Announces Appointment of Anthony Bruno to Board of Directors
REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and ...
November 19, 2018
Anchiano Therapeutics Reports Third Quarter 2018 Financial and Operational Results
CAMBRIDGE, Mass., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics (ANCN.TA), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to ...
November 19, 2018
TRACON Pharmaceuticals Presents Data from Phase 2 Trial of TRC102 and Temodar® in Patients with Recurrent Glioblastoma at Society for Neuro-Oncology Annual Meeting
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
November 19, 2018
OncoCyte Corporation to Present at the Piper Jaffray 30th Annual Health Care Conference
ALAMEDA, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung ...
November 19, 2018
EMERGENT BIOSOLUTIONS AND VALNEVA REPORT POSITIVE PHASE 1 RESULTS FOR THEIR VACCINE CANDIDATE AGAINST THE ZIKA VIRUS
GAITHERSBURG, Md. and Saint-Herblain, France, November 19, 2018 - Emergent BioSolutions Inc. (EBS) and Valneva SE (VLA) today announced positive interim results for the Phase ...
November 15, 2018
Prometic Reports Third Quarter 2018 Financial Results and Highlights
LAVAL, QC, Nov. 14, 2018 /PRNewswire/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic or the Corporation) reported today its unaudited financial results for the third quarter ...
November 15, 2018
Celyad to Participate at Upcoming Healthcare Conferences
MONT-SAINT-GUIBERT, Belgium, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of ...
November 15, 2018
INNATE PHARMA : Third quarter 2018 report
Marseille, France, November 15, 2018, 7:00 AM CET - Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announced its revenues and cash ...
November 15, 2018
AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease
Lausanne, Switzerland, November 15, 2018 - AC Immune SA (ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced ...
November 15, 2018
Sierra Oncology Reports Preclinical Efficacy for Chk1 inhibitor SRA737 in Treatment Refractory Ovarian Cancer Models at the EORTC-NCI-AACR Symposium
VANCOUVER, Nov. 15, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients ...
November 15, 2018
Arena Pharmaceuticals and United Therapeutics Announce Global License Agreement for Ralinepag
SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Nov. 15, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) and United Therapeutics Corporation (UTHR) today announced that the companies ...
November 15, 2018
Heat Biologics Reports Third Quarter 2018 Results and Provides Corporate Update
DURHAM,NC / ACCESSWIRE / November 15, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against ...
November 15, 2018
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results
REDWOOD CITY, Calif., Nov. 15, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of ...
Page 37 of 150